BioDelivery Sciences International Company Profile (NASDAQ:BDSI)

About BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International logoBioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:BDSI
  • CUSIP: 09060J10
  • Web: www.bdsi.com
Capitalization:
  • Market Cap: $155.33 million
  • Outstanding Shares: 55,475,000
Average Prices:
  • 50 Day Moving Avg: $3.08
  • 200 Day Moving Avg: $2.47
  • 52 Week Range: $1.50 - $3.60
P/E:
  • Trailing P/E Ratio: 100.00
  • Foreward P/E Ratio: -4.38
  • P/E Growth: 0.93
Sales & Book Value:
  • Annual Revenue: $44.33 million
  • Price / Sales: 3.50
  • Book Value: $0.47 per share
  • Price / Book: 5.96
Profitability:
  • EBIDTA: ($31,810,000.00)
  • Net Margins: 3.34%
  • Return on Equity: 14.64%
  • Return on Assets: 1.90%
Debt:
  • Debt-to-Equity Ratio: 1.34%
  • Current Ratio: 1.45%
  • Quick Ratio: 1.24%
Misc:
  • Average Volume: 541,203 shs.
  • Beta: 1.04
  • Short Ratio: 6.2
 

Frequently Asked Questions for BioDelivery Sciences International (NASDAQ:BDSI)

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.04. The business earned $8.70 million during the quarter, compared to analysts' expectations of $8.45 million. BioDelivery Sciences International had a return on equity of 14.64% and a net margin of 3.34%. BioDelivery Sciences International's revenue for the quarter was up 74.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.31) EPS. View BioDelivery Sciences International's Earnings History.

When will BioDelivery Sciences International make its next earnings announcement?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for BioDelivery Sciences International.

Where is BioDelivery Sciences International's stock going? Where will BioDelivery Sciences International's stock price be in 2017?

6 equities research analysts have issued 12 month price objectives for BioDelivery Sciences International's stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $4.42 in the next year. View Analyst Ratings for BioDelivery Sciences International.

What are analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:

  • 1. According to Zacks Investment Research, "BioDelivery’s has secured improved positioning in six new managed care contracts providing preferred access to its key drug Bunavail since July last year, which is expected to boost the drug’s sales and profitability in 2017. Moreover, its second marketed drug Belbuca’s sales hit all-time high since the product was launched a year ago. However, the company recently discontinued development of clonidine topical gel for management of painful diabetic neuropathy. BioDelivery’s portfolio as well as its pipeline candidates may also face sever competition as it targets a highly genericized and crowded market. Its share significantly outperformed the Zacks classified Medical-Biomed/Genetics market so far this year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (7/17/2017)
  • 2. Cantor Fitzgerald analysts commented, "A Lot of Moving Parts and 1x Items: BDSI reported 1Q17 results posting net income of $0.89, the majority of which was attributed to positive effects of the Belbuca return. These items included $20M in deferred revenue recognition, $27M in non-cash bargain purchase gain and a $16M tax benefit. Without these additions, BDSI would have reported a loss of ($0.23). BDSI finished 1Q with $35.2M in cash, which the company estimates should fund operations into 2H18. We have adjusted our estimates to reflect quarter and year end results. Alignment of Fundamentals: We have watched the re-launch of Belbuca closely following the ENDP transition with the recently expanded sales force growing Rx numbers through 1Q and April, per Symphony data. More importantly, $/Rx continues to increase with due to larger prescriptions and incremental price increases. We also note a significant shift to commercial payor which should allow for increased gross/net adding to the top-line. The expanded sales force of 65 armed with revised marketing messaging, particularly around titration, has been targeting physicians familiar with the buprenorphine molecule with success, in our view. We believe additional education campaigns such as speaker programs and a PAINWeekEND symposium will drive interest. Additional Upside: We see additional upside as BDSI focuses on managed Medicaid contracts of which BDSI as of Feb." (5/16/2017)
  • 3. FBR & Co analysts commented, "BioDelivery reported 4Q16 results after the close on March 16. On the morning of March 17, management hosted a call to provide an update on 2017 progress. The company recently announced that it has entered into a senior credit facility with affiliates of CRG LP , which is a healthcare-focused investment firm, and currently has debt financing of up to $75M secured, with initial proceeds extending the company’s cash runway into 2H18." (3/20/2017)

Who are some of BioDelivery Sciences International's key competitors?

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:

  • Frank E. O'Donnell Jr., M.D., Executive Chairman of the Board
  • Mark A. Sirgo, Vice Chairman of the Board
  • Ernest R. De Paolantonio CPA, Chief Financial Officer, Treasurer, Secretary
  • Niraj Vasisht Ph.D., Senior Vice President of Product Development and Chief Technical Officer
  • Peter L. Ginsberg, Vice President - Business Development
  • William B. Stone, Lead Independent Director
  • Timothy C. Tyson, Director
  • Charles J. Bramlage, Independent Director
  • Thomas W. D'Alonzo, Independent Director
  • Barry I. Feinberg M.D., Independent Director

Who owns BioDelivery Sciences International stock?

BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (9.23%), Stonepine Capital Management LLC (6.27%), Vanguard Group Inc. (3.54%), Ameriprise Financial Inc. (3.43%), Blair William & Co. IL (2.66%) and Bank of Montreal Can (1.30%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Charles Bramlage, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr, Thomas D'alonzo and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

Who sold BioDelivery Sciences International stock? Who is selling BioDelivery Sciences International stock?

BioDelivery Sciences International's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Vanguard Group Inc., Broadfin Capital LLC, Virtu KCG Holdings LLC and GRT Capital Partners L.L.C.. Company insiders that have sold BioDelivery Sciences International stock in the last year include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De and Samuel P Sears, Jr. View Insider Buying and Selling for BioDelivery Sciences International.

Who bought BioDelivery Sciences International stock? Who is buying BioDelivery Sciences International stock?

BioDelivery Sciences International's stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Stonepine Capital Management LLC, EAM Investors LLC, Hikari Power Ltd, Sterling Investment Management Inc., GSA Capital Partners LLP, Valley National Advisers Inc. and Advisor Group Inc.. Company insiders that have bought BioDelivery Sciences International stock in the last two years include Barry I Feinberg, Charles Bramlage, Niraj Vasisht, Paolantonio Ernest Robert De and Thomas D'alonzo. View Insider Buying and Selling for BioDelivery Sciences International.

How do I buy BioDelivery Sciences International stock?

Shares of BioDelivery Sciences International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BioDelivery Sciences International stock can currently be purchased for approximately $2.80.


MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioDelivery Sciences International (NASDAQ:BDSI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $4.42 (57.74% upside)

Analysts' Ratings History for BioDelivery Sciences International (NASDAQ:BDSI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/10/2017HC WainwrightInitiated CoverageBuy$5.00MediumView Rating Details
8/20/2017Cantor FitzgeraldReiterated RatingOverweightMediumView Rating Details
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$4.00HighView Rating Details
7/24/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$3.00 -> $4.00HighView Rating Details
5/16/2017Roth CapitalSet Price TargetBuy$5.00MediumView Rating Details
5/16/2017FBR & CoSet Price TargetBuy$4.00MediumView Rating Details
3/14/2016LaidlawLower Price TargetBuy$17.00 -> $11.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)
Earnings by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Earnings History by Quarter for BioDelivery Sciences International (NASDAQ BDSI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.22)N/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.27)$8.45 million$8.70 millionViewListenView Earnings Details
5/15/2017Q1 2017$0.09$0.58$27.07 million$29.48 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.26)($0.29)$6.37 million$3.90 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.30)$3.58 million$3.60 millionViewListenView Earnings Details
8/9/2016Q216($0.31)($0.31)$3.35 million$5.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.35)($0.36)$2.96 million$3.00 millionViewListenView Earnings Details
3/10/2016Q415$0.55$0.19$52.40 million$32.20 millionViewListenView Earnings Details
11/9/2015Q315($0.34)($0.39)$1.56 million$1.20 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.37)$3.29 million$1.70 millionViewListenView Earnings Details
5/11/2015Q115($0.20)($0.16)$10.80 million$13.10 millionViewListenView Earnings Details
3/16/2015Q414($0.40)($0.51)$4.00 million$2.50 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.29)($0.39)$3.02 million$1.82 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.07)($0.14)$11.65 million$13.89 millionViewN/AView Earnings Details
5/9/2014Q114($0.15)($0.11)$11.60 million$20.69 millionViewN/AView Earnings Details
3/14/2014($0.22)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioDelivery Sciences International (NASDAQ:BDSI)
2017 EPS Consensus Estimate: ($0.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.22)$0.09($0.10)
Q2 20173($0.31)($0.20)($0.25)
Q3 20173($0.28)($0.23)($0.25)
Q4 20173($0.27)($0.21)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioDelivery Sciences International (NASDAQ:BDSI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioDelivery Sciences International (NASDAQ:BDSI)
Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 41.43%
Insider Trades by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Insider Trades by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2017Mark A SirgoInsiderSell201,373$2.84$571,899.32View SEC Filing  
9/20/2017Mark A SirgoCEOSell65,405$2.75$179,863.75View SEC Filing  
9/19/2017Mark A SirgoCEOSell24,516$2.75$67,419.00View SEC Filing  
9/18/2017Mark A SirgoCEOSell6,000$2.85$17,100.00View SEC Filing  
9/15/2017Mark A SirgoCEOSell54,833$2.90$159,015.70View SEC Filing  
9/14/2017Mark A SirgoCEOSell50,000$2.95$147,500.00View SEC Filing  
3/31/2017Mark A SirgoCEOSell110,895$1.90$210,700.50View SEC Filing  
3/23/2017Francis E Odonnell JrDirectorSell750$1.90$1,425.00View SEC Filing  
3/23/2017Niraj VasishtSVPSell530$1.90$1,007.00View SEC Filing  
3/23/2017Paolantonio Ernest Robert DeCFOSell170$1.90$323.00View SEC Filing  
1/30/2017Niraj VasishtInsiderSell6,905$1.91$13,188.55View SEC Filing  
12/1/2016Samuel P. Sears, Jr.DirectorSell12,000$1.67$20,040.00View SEC Filing  
11/23/2016Barry I FeinbergDirectorBuy2,000$1.67$3,340.00View SEC Filing  
11/17/2016Barry I FeinbergDirectorBuy3,000$1.87$5,610.00View SEC Filing  
9/23/2016Francis E Odonnell JrDirectorSell100,000$2.57$257,000.00View SEC Filing  
9/23/2016Niraj VasishtInsiderSell47,000$2.43$114,210.00View SEC Filing  
9/22/2016Paolantonio Ernest Robert DeCFOSell14,800$2.44$36,112.00View SEC Filing  
8/25/2016Barry I FeinbergDirectorBuy2,500$2.55$6,375.00View SEC Filing  
8/11/2016William B StoneDirectorSell16,000$2.57$41,120.00View SEC Filing  
3/21/2016Charles BramlageDirectorBuy8,850$2.82$24,957.00View SEC Filing  
3/18/2016Barry I FeinbergDirectorBuy10,000$2.74$27,400.00View SEC Filing  
3/18/2016Niraj VasishtCTOBuy1,000$2.80$2,800.00View SEC Filing  
3/17/2016Paolantonio Ernest Robert DeCFOBuy4,000$2.60$10,400.00View SEC Filing  
11/24/2015Francis E Odonnell JrDirectorSell50,000$6.01$300,500.00View SEC Filing  
11/13/2015Thomas D'alonzoDirectorBuy4,528$5.52$24,994.56View SEC Filing  
9/3/2015Francis E Odonnell JrDirectorSell20,000$6.43$128,600.00View SEC Filing  
8/26/2015Paolantonio Ernest Robert DeCFOBuy1,650$6.20$10,230.00View SEC Filing  
8/13/2015William B StoneDirectorSell11,500$7.01$80,615.00View SEC Filing  
6/16/2015Francis E Odonnell JrDirectorSell21,597$8.03$173,423.91View SEC Filing  
6/16/2015Mark A SirgoCEOSell4,187$7.97$33,370.39View SEC Filing  
5/26/2015Barry I FeinbergDirectorBuy2,000$7.84$15,680.00View SEC Filing  
5/14/2015Barry I FeinbergDirectorBuy2,000$8.54$17,080.00View SEC Filing  
5/13/2015Thomas D'alonzoDirectorBuy6,226$8.07$50,243.82View SEC Filing  
12/26/2014Francis E Odonnell JrDirectorSell70,000$12.00$840,000.00View SEC Filing  
12/15/2014Mark A SirgoCEOBuy2,500$12.23$30,575.00View SEC Filing  
12/10/2014Samuel P Sears JrDirectorSell7,853$15.03$118,030.59View SEC Filing  
11/12/2014William B StoneDirectorSell14,000$16.11$225,540.00View SEC Filing  
9/4/2014Barry I FeinbergDirectorBuy1,000$15.18$15,180.00View SEC Filing  
9/4/2014Mark A SirgoCEOBuy2,000$15.04$30,080.00View SEC Filing  
8/27/2014Andrew L FinnEVPSell90,000$15.00$1,350,000.00View SEC Filing  
8/22/2014Charles BramlageDirectorBuy1,800$13.85$24,930.00View SEC Filing  
6/25/2014Paolantonio Ernest Robert DeCFOBuy1,250$12.13$15,162.50View SEC Filing  
6/12/2014Samuel P Sears JrDirectorSell5,000$12.33$61,650.00View SEC Filing  
6/11/2014Francis E Odonnell JrDirectorSell125,000$11.04$1,380,000.00View SEC Filing  
3/26/2014Francis Odonnell, Jr.DirectorSell50,000$8.04$402,000.00View SEC Filing  
3/20/2014Samuel Sears, Jr.DirectorSell4,000$9.00$36,000.00View SEC Filing  
3/11/2014Andrew FinnEVPSell80,000$9.99$799,200.00View SEC Filing  
3/11/2014William StoneDirectorSell35,000$10.00$350,000.00View SEC Filing  
2/20/2014Andrew FinnEVPSell18,737$8.84$165,635.08View SEC Filing  
2/20/2014Francis Odonnell, Jr.DirectorSell70,000$8.92$624,400.00View SEC Filing  
2/20/2014Mark SirgoCEOSell42,000$8.92$374,640.00View SEC Filing  
1/24/2014Andrew FinnEVPSell143,679$9.03$1,297,421.37View SEC Filing  
1/24/2014James McnultySVPSell89,223$8.73$778,916.79View SEC Filing  
1/24/2014John SheaDirectorSell130,000$8.78$1,141,400.00View SEC Filing  
1/24/2014Mark SirgoCEOSell116,253$9.01$1,047,439.53View SEC Filing  
11/18/2013Mark SirgoCEOBuy2,337$4.29$10,025.73View SEC Filing  
9/19/2013Francis Odonnell, Jr.DirectorSell95,000$5.36$509,200.00View SEC Filing  
9/11/2013Samuel P Sears JrDirectorSell2,000$5.37$10,740.00View SEC Filing  
9/9/2013Samuel P Sears JrDirectorSell7,500$5.05$37,875.00View SEC Filing  
8/26/2013Andrew FinnEVPBuy5,000$4.58$22,900.00View SEC Filing  
8/16/2013Mark SirgoCEOBuy5,100$4.43$22,593.00View SEC Filing  
8/15/2013William StoneDirectorSell6,825$4.44$30,303.00View SEC Filing  
8/14/2013James McnultyCFOBuy5,000$4.50$22,500.00View SEC Filing  
6/21/2013Mark A SirgoCEOBuy3,400$4.30$14,620.00View SEC Filing  
6/20/2013Francis E Odonnell JrDirectorSell72,689$4.36$316,924.04View SEC Filing  
6/5/2013Samuel P Sears JrDirectorSell5,000$4.42$22,100.00View SEC Filing  
12/21/2012Andrew L FinnEVPBuy3,000$3.85$11,550.00View SEC Filing  
12/21/2012Mark A SirgoCEOBuy4,975$4.02$19,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioDelivery Sciences International (NASDAQ:BDSI)
Latest Headlines for BioDelivery Sciences International (NASDAQ:BDSI)
Source:
DateHeadline
americanbankingnews.com logoMark A. Sirgo Sells 6,000 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - September 22 at 8:40 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) CEO Mark A. Sirgo Sells 24,516 Shares
www.americanbankingnews.com - September 22 at 8:18 PM
americanbankingnews.com logoMark A. Sirgo Sells 50,000 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - September 22 at 8:16 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) CEO Mark A. Sirgo Sells 65,405 Shares
www.americanbankingnews.com - September 22 at 8:16 PM
americanbankingnews.com logoMark A. Sirgo Sells 54,833 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - September 22 at 8:16 PM
americanbankingnews.com logoInsider Selling: BioDelivery Sciences International, Inc. (BDSI) Insider Sells 201,373 Shares of Stock
www.americanbankingnews.com - September 22 at 7:52 PM
americanbankingnews.com logoBioDelivery Sciences International (BDSI) vs. Its Rivals Financial Review
www.americanbankingnews.com - September 22 at 4:26 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 20 at 9:24 AM
nasdaq.com logoMid-Afternoon Market Update: Crude Oil Down Over 1%; Synchronoss Technologies Shares Slide - Nasdaq
www.nasdaq.com - September 19 at 9:29 PM
prnewswire.com logoBioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann ... - PR Newswire (press release)
www.prnewswire.com - September 19 at 9:29 PM
finance.yahoo.com logoBioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 19 at 4:28 PM
americanbankingnews.com logo-$0.23 Earnings Per Share Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
www.americanbankingnews.com - September 19 at 12:26 AM
streetinsider.com logoBioDelivery Sciences (BDSI) Secures Market Authorization Transfer by Health Canada for BELBUCA and Associated Milestone Payment
www.streetinsider.com - September 14 at 10:09 PM
seekingalpha.com logoBioDelivery Sciences (BDSI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:40 PM
streetinsider.com logoBioDelivery Sciences (BDSI) Secures Market Authorization Transfer by Health Canada for BELBUCA and Associated ... - StreetInsider.com
www.streetinsider.com - September 12 at 4:39 PM
finance.yahoo.com logoBioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment
finance.yahoo.com - September 12 at 4:39 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Now Covered by HC Wainwright
www.americanbankingnews.com - September 10 at 6:24 AM
prnewswire.com logoBioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference - PR Newswire (press release)
www.prnewswire.com - September 7 at 4:31 PM
finance.yahoo.com logoBioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference
finance.yahoo.com - September 7 at 4:30 PM
americanbankingnews.com logoValuEngine Lowers BioDelivery Sciences International, Inc. (BDSI) to Sell
www.americanbankingnews.com - September 3 at 9:00 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $8.89 Million
www.americanbankingnews.com - September 2 at 9:30 AM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 26 at 11:04 AM
prnewswire.com logoBioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - August 25 at 1:00 AM
finance.yahoo.com logoBioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - August 24 at 4:30 PM
finance.yahoo.com logoBioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
finance.yahoo.com - August 24 at 4:30 PM
streetinsider.com logoBioDelivery Sciences (BDSI) CEO Dr. Mark A. Sirgo to Retire, Continue as Vice Chairman
www.streetinsider.com - August 23 at 4:37 PM
finance.yahoo.com logoBioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman
finance.yahoo.com - August 23 at 4:37 PM
finance.yahoo.com logoBDSI CEO to retire
finance.yahoo.com - August 23 at 4:37 PM
americanbankingnews.com logoCantor Fitzgerald Comments on BioDelivery Sciences International, Inc.'s FY2017 Earnings (BDSI)
www.americanbankingnews.com - August 23 at 8:38 AM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Receives Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 23 at 8:36 AM
finance.yahoo.com logoBioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017
finance.yahoo.com - August 17 at 5:51 PM
americanbankingnews.com logo Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) Will Announce Quarterly Sales of $8.75 Million
www.americanbankingnews.com - August 15 at 1:40 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Earns Overweight Rating from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - August 14 at 8:36 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for BioDelivery Sciences International, Inc. Boosted by Analyst (NASDAQ:BDSI)
www.americanbankingnews.com - August 14 at 3:36 AM
americanbankingnews.com logo-$0.25 EPS Expected for BioDelivery Sciences International, Inc. (NASDAQ:BDSI) This Quarter
www.americanbankingnews.com - August 13 at 2:24 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Portola Pharmaceuticals and BioDelivery Sciences International
finance.yahoo.com - August 11 at 4:56 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Portola Pharmaceuticals and BioDelivery Sciences International
finance.yahoo.com - August 11 at 4:56 PM
finance.yahoo.com logoEdited Transcript of BDSI earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 10:50 PM
nasdaq.com logoBioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls - Nasdaq
www.nasdaq.com - August 10 at 5:37 PM
finance.yahoo.com logoBioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
finance.yahoo.com - August 10 at 5:37 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 10 at 3:42 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Given a $4.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - August 10 at 9:08 AM
seekingalpha.com logoBioDelivery Sciences International's (BDSI) CEO Mark Sirgo on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 2:42 AM
prnewswire.com logoBioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)
www.prnewswire.com - August 9 at 4:37 PM
finance.yahoo.com logoWhat's in Store for BioDelivery (BDSI) This Earnings Season? - Yahoo Finance
finance.yahoo.com - August 9 at 4:37 PM
finance.yahoo.com logoBioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 4:37 PM
finance.yahoo.com logoBioDelivery reports 2Q loss
finance.yahoo.com - August 9 at 4:37 PM
finance.yahoo.com logoETFs with exposure to BioDelivery Sciences International, Inc. : August 7, 2017
finance.yahoo.com - August 7 at 9:08 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (NASDAQ:BDSI) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 1 at 11:08 AM
prnewswire.com logoBioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update - PR Newswire (press release)
www.prnewswire.com - July 31 at 3:24 PM

Social

Chart

BioDelivery Sciences International (BDSI) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff